Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M
Department of General Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuoh-ku, Chiba 260-8670, Japan.
Br J Surg. 2002 Dec;89(12):1525-31. doi: 10.1046/j.1365-2168.2002.02268.x.
The results of surgical treatment for intrahepatic cholangiocarcinoma (ICC) and specific factors influencing survival are still unclear.
Between 1984 and 2001, 62 patients with ICC underwent laparotomy, with a 77 per cent (48 patients) resectability rate. The tumours in these 48 patients were reviewed retrospectively to examine the relationship between gross appearance (mass forming, periductal infiltrating, intraductal growth, and mass forming plus periductal infiltrating) and patient survival, as well as the manner of recurrence. In patients with mass-forming and mass-forming plus periductal infiltrating types, univariate and multivariate analyses of potential prognostic factors were performed.
The 1-, 3- and 5-year survival rates were 62, 38 and 23 per cent respectively. All patients with the intraductal growth type remained alive after intervals ranging from 8 to 72 months. Univariate analysis showed multiple hepatic lesions, liver capsule invasion, presence of cancer cells in the resection margin, and high serum carbohydrate antigen (CA) 19-9 level to be significant negative prognostic factors. Lymph node involvement, however, was not identified as a significant prognostic factor. With multivariate analysis, multiple hepatic lesions and high serum CA19-9 concentration were found to be significantly related to prognosis. The most frequent recurrence site was the remnant liver.
These results suggest that the intraductal growth type of tumour should be treated as a distinct entity compared with other types of ICC. Multiple tumours and high serum CA19-9 level were signs of dismal prognosis, whereas not all patients with lymph node involvement had a poor prognosis.
肝内胆管癌(ICC)的手术治疗结果以及影响生存的特定因素仍不明确。
1984年至2001年间,62例ICC患者接受了剖腹手术,可切除率为77%(48例患者)。对这48例患者的肿瘤进行回顾性分析,以研究大体外观(肿块形成、导管周围浸润、导管内生长以及肿块形成加导管周围浸润)与患者生存之间的关系,以及复发方式。对于肿块形成型和肿块形成加导管周围浸润型患者,对潜在预后因素进行单因素和多因素分析。
1年、3年和5年生存率分别为62%、38%和23%。所有导管内生长型患者在8至72个月的随访期后均存活。单因素分析显示,多发肝内病变、肝包膜侵犯、切缘癌细胞阳性以及血清糖类抗原(CA)19-9水平升高是显著的负性预后因素。然而,淋巴结受累未被确定为显著的预后因素。多因素分析发现,多发肝内病变和高血清CA19-9浓度与预后显著相关。最常见的复发部位是残肝。
这些结果表明,与其他类型的ICC相比,肿瘤的导管内生长型应被视为一种独特的实体。多发肿瘤和高血清CA19-9水平是预后不良的征象,而并非所有淋巴结受累患者的预后都很差。